Skip to main content

Pacira BioSciences, Inc.

corporate_fare Company Profile

Pacira BioSciences, Inc.

PCRX·NASDAQ·Life Sciences·CIK 0001396814

Pacira BioSciences, Inc. is a Delaware corporation that serves as the holding company for its California operating subsidiary, Pacira Pharmaceuticals, Inc. The company's mission is to deliver innovative, non-opioid pain therapies. Pacira BioSciences, Inc. was incorporated in Delaware in December 2006 as Blue Acquisition Corp., changing its name to Pacira, Inc. in June 2007, then to Pacira Pharmaceuticals, Inc. in October 2010, and finally to Pacira BioSciences, Inc. in April 2019. Its principal executive offices and corporate headquarters are located in Brisbane, California. The company has expanded through several acquisitions. In March 2007, it acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.). In April 2019, Pacira BioSciences, Inc. acquired MyoScience, Inc., a privately held medical technology company. This was followed by the acquisition of Flexion Therapeutics, Inc., a publicly traded biopharmaceutical company, in November 2021. Most recently, in February 2025, the company acquired GQ Bio Therapeutics GmbH, a privately-held biopharmaceutical company. Key trademarks and service marks owned by Pacira include Pacira®, EXPAREL®, ZILRETTA®, iovera®°, and the Pacira logo.

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for PCRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Pacira BioSciences Faces Contested Director Election and Seeks Approval for Significant Equity Plan Expansion Amidst Activist Pressure
  • New Data Shows Pacira's EXPAREL Lowers Healthcare Costs, Opioid Use in Outpatient Orthopedic Surgeries
  • Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement and Company Sale
  • Pacira Counters Activist Investor, Highlights Strategic Progress and Shareholder Returns
  • Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement & Formal Sale Process for Pacira BioSciences

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$726.41M
Net Income
$7.03M
Diluted EPS
$0.16
Op. Cash Flow
$151.99M
Free Cash Flow
$136.66M
Gross Profit
$576.66M
Operating Income
$19.19M
Cash & Equivalents
$158.54M
Total Debt
$372.19M
Debt / Equity
0.54×
Net Margin
1.0%
Shares Outstanding
41.12M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012297
$36.49
52-week range · as of 2026-11-12 $18.8 – $36.66
Market cap
$1.46B
Volume
1.8M (0.8× avg)
3-mo avg 2.2M
Last traded · 2026-11-18

show_chartPrice Chart

Loading chart...

feed PCRX - Filings & News (Page 3)

PCRX
Apr 17, 2026, 4:15 PM EDT
Filing Type: PREC14A
Importance Score:
8
Price at Filing: $24.72
Real-time Price: $36.49 info
Change: +$11.77 (+48%) info
Market Cap: $1.463B info
PCRX
Apr 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $23.79
Real-time Price: $36.49 info
Change: +$12.70 (+53%) info
Market Cap: $1.463B info
PCRX
Mar 12, 2026, 7:57 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $23.53
Real-time Price: $36.49 info
Change: +$12.96 (+55%) info
Market Cap: $1.463B info
PCRX
Mar 11, 2026, 5:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $22.83
Real-time Price: $36.49 info
Change: +$13.66 (+60%) info
Market Cap: $1.463B info
PCRX
Mar 11, 2026, 3:25 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $22.87
Real-time Price: $36.49 info
Change: +$13.62 (+60%) info
Market Cap: $1.463B info
PCRX
Mar 11, 2026, 1:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.82
Real-time Price: $36.49 info
Change: +$13.67 (+60%) info
Market Cap: $1.463B info
PCRX
Feb 26, 2026, 4:16 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $21.33
Real-time Price: $36.49 info
Change: +$15.16 (+71%) info
Market Cap: $1.463B info
PCRX
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $21.53
Real-time Price: $36.49 info
Change: +$14.96 (+69%) info
Market Cap: $1.463B info
PCRX
Jan 28, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.85
Real-time Price: $36.49 info
Change: +$16.64 (+84%) info
Market Cap: $1.463B info
PCRX
Jan 08, 2026, 7:16 PM EST
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $25.65
Real-time Price: $36.49 info
Change: +$10.84 (+42%) info
Market Cap: $1.463B info
PCRX
Jan 08, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $26.02
Real-time Price: $36.49 info
Change: +$10.47 (+40%) info
Market Cap: $1.463B info
PCRX
Jan 02, 2026, 12:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $24.65
Real-time Price: $36.49 info
Change: +$11.84 (+48%) info
Market Cap: $1.463B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets